

GINNY VACHON, PhD

CEO, PRINCIPAL MEDVANTAGE, LLC



CONTACT

📍 165 Courtland St., Ste. A - #209
Atlanta, GA 30303

✉ ginny@principalmedvantage.com

☎ 404-307-5906

EDUCATION

PhD in Microbiology and Molecular Genetics
Emory University, 2015
Innate immune proteins and regulatory noncoding RNA and biochemistry

BA in Biology
Agnes Scott College, 2007

PRINCIPAL MEDVANTAGE WRITING, LLC – Medical Writing Support for Meetings

CEO – 2015 to Present

Ensuring that clients get the most from their meetings by producing quality notes, top-line reports, executive summaries, white papers, and articles that capture the central themes of the meeting and every important insight that emerges

- Personable, diligent, client-facing medical writer
- Ability to travel
- Strong communication and organization skills
- Experienced in generating thorough reports from unrecorded meetings
- Expertly organize and present scientific information in a concise, accessible, and visually pleasing manner

Attending clinical and commercial drug and device advisory board meetings and providing the following deliverables:

- **Executive summary reports**, including automatic response system data, presented information, and discussion surrounding themes
- **Complex summary reports** comparing and contrasting findings in different regions or among different specialists
- **White papers** from meeting proceedings
- **Top-line PowerPoint presentations** on the meeting's overarching themes
- **Notes** on presented information, discussion points, consensuses, points of dissention, and advisor recommendations
- **Supplements** for publication or internal use
- **Articles** for publication or internal use

AREAS OF EXPERTISE

Aesthetic Medicine

- Attended a **roundtable** and generated 6 **supplements** comparing and contrasting dermatologic fillers and detailing methods for hand rejuvenation, volume correction, and prevention and treatment of adverse events
 - Goldberg DJ, Bass LM, Fitzgerald R, Graivier MH, Lorenc ZP. Expanding Treatment Options for Injectable Agents. *Aesthet Surg J.* 2018; 8: S1-S7.
 - Lorenc ZP, Bass LM, Fitzgerald R, Goldberg DJ, Graivier MH. Physiochemical Characteristics of Calcium Hydroxylapatite (CaHA). *Aesthet Surg J.* 2018; 8: S8-S12.
 - Fitzgerald R, Bass LM, MD; Goldberg DJ, Graivier MH, Lorenc ZP. Physiochemical Characteristics of Poly-L-Lactic Acid (PLLA). *Aesthet Surg J.* 2018; 8: S13-S17.
 - Lorenc ZP, Bass LM, Fitzgerald R, Goldberg DJ, Graivier MH. Composite Facial Volumization With Calcium Hydroxylapatite (CaHA) for the Treatment of Aging. *Aesthet Surg J.* 2018; 8: S18-S23.
 - Graivier MH, Lorenc ZP, Bass LM, Fitzgerald R, Goldberg DJ. Calcium Hydroxyapatite (CaHA) Indication for Hand Rejuvenation. *Aesthet Surg J.* 2018; 8: S24-S28.
 - Graivier MH, Lorenc ZP, Bass LM, Fitzgerald R, Goldberg DJ. Differentiating Nonpermanent Injectable Fillers: Prevention and Treatment of Filler Complications. *Aesthet Surg J.* 2018; 8: S29-S39.
- Created an executive summary for an advisory board on the adoption of suspension sutures in the United States
- Prepared articles on the application of suspension sutures based on roundtable proceedings
 - *Expert Consensus on Achieving Optimal Outcomes With Absorbable Suspension Suture Technology for Tissue Repositioning and Facial Recontouring* – submitted to *Journal of Drugs in Dermatology*
 - *Straight-Line Vector Planning for Optimal Results With Silhouette InstaLift in Minimally Invasive Tissue Repositioning for Facial Rejuvenation* – submitted to *Aesthetic Plastic Surgery*

Association Meetings

- Prepared a white paper upon discussion of shared decision-making strategies and considerations surrounding PSA testing during a seminar on improved outcomes hosted by the **American Urological Association**
- Generated a white paper for the **American Urological Association** based on discussion of experiences surrounding CT dose optimization in the diagnosis and management of kidney stones

Clinical Practice

- Attended **advisory boards** and provided **top-line reports and executive summaries** on how new drugs fit into the treatment paradigm for the following conditions:
 - Acute hepatic porphyria
 - Allergy and chronic inflammation
 - Asthma
 - Attention deficit hyperactivity disorder
 - Cardiovascular disease
 - Chronic idiopathic urticaria
 - Chronic kidney disease (anemia and hypophosphatemia in both predialysis and dialysis patients)
 - Diabetes
 - Duchenne muscular dystrophy
 - Multiple sclerosis
 - Neurological disorders
 - Ophthalmology (dry eye disease and ocular inflammation)
 - Osteoarthritis
- Prepared a **white paper** on CT dose optimization in a multihospital initiative

Clinical Trial Organization and Feedback

- Roundtable reviews of **protocols** and **phase I and II clinical data**, as well as advisor feedback on clinical trial organization and future clinical trials on topics including:
 - Autoimmune diseases
 - hATTR amyloidosis
 - Primary immune deficiency (PID)
 - Complement-mediated diseases
 - Cystic fibrosis
 - Diabetes
 - Chronic liver disease
 - Familial chylomicronemia syndrome
 - Gene therapy
 - Hemophilia A and B (including disease management, Factor VII and IX, and inhibitors)
 - Myasthenia graves
 - Paroxysmal nocturnal hemoglobinuria
 - Pyruvate kinase deficiency
- Executive summary detailing meeting proceedings, next steps, and recommendations for guidelines for the **Clinical Trials Transformation Initiative (CTTI)** concerning:
 - Investigator qualification
 - Central institutional review board (IRB)
- Notes detailing merit review proceedings for communications, dissemination, and implementation research for the **Patient-Centered Research Outcomes Institute (PCORI)**

Comparing and Contrasting Regional Practices

- Prepared an **executive report** to compare and contrast provider perceptions of clinical data and how the drug discussed fits into the current **diabetes** treatment paradigm
 - Reviewed diabetes treatment approaches by different care providers (primary care providers [PCPs], nurse practitioners, and community and academic endocrinologists)
- Created an **executive summary** that detailed factors shaping advisors' diabetes therapy selection decisions in geographic regions of interest
 - Prepared a **regional report** that compared and contrasted practices of 7 regions on diabetes treatment approaches by community PCPs
- Created **top-line reports** from interdisciplinary meetings bringing together thought leaders in 6 geographic regions focusing on disease management and diagnostic challenges and strategies for **hATTR amyloidosis** and created a full **executive report comparing and contrasting regional practices**

Continuing Medical Education (CME)

Completion of needs assessments in a variety of subjects, including:

- Bladder cancer
- Cancer metabolism
- Diabetes
- Inflammation
- mTor kinase inhibitors
- PD-1 inhibitors
- Tuberous sclerosis

Devices

- Prepared **executive summaries** on physician experiences with devices for:
 - High-dose rate brachytherapy in prostate cancer
 - Brachytherapy for basal cell carcinoma
 - Absorbable suspension sutures for tissue repositioning
 - Insulin delivery
- Developed a **combined self-assessment tool** for understanding quality of life measures for patients with life-limiting illnesses
- Developed strategies for promoting “whole person health” in primary care through the use of a **self-assessment tool**

Government and Regulatory Meetings

- Report on the patient experience for C3G Dense Deposit Disease and C3 Glomerulonephritis for the **Food and Drug Administration (FDA)** and **National Kidney Foundation – Voice of the Patient** meeting
- Provided an **AHRQ meeting report** on the best clinical practices and research gaps surrounding antibiotic stewardship for the **Centers for Disease Control and Prevention (CDC) Meeting on Antibiotic Stewardship** (for the CDC and the Agency for Healthcare Research and Quality)

Meeting Moderation and Physician Interviews

- Conducted interviews with **cardiovascular surgeons** at Piedmont Hospital in Atlanta, GA on the following topics:
 - Transcatheter aortic valve replacement
 - Successful percutaneous coronary intervention (PCI) for clearance of chronic total occlusion (CTO)
 - Control of refractory hypertension
 - Reduction of critical wait times for kidney transplant
 - Challenges in liver transplant allocation
- Interviewed plastic surgeons on topics related to **dermatologic fillers** for manuscript development

Oncology

- Covered advisory panels and meetings including, but not limited to:
 - Regional variation in physician attitudes on therapy use and sequencing for the treatment of the following cancers:
 - Gastrointestinal
 - Non-small cell lung cancer
 - Metastatic castration-resistant prostate cancer
 - Follicular lymphoma
 - Chronic lymphocytic leukemia
 - Chronic myelogenous leukemia
 - Polycythemia vera
 - For each of these cancer types, **top-line reports** and **executive summaries** were generated for between 4 and 10 regions within the United States, along with a final report comparing and contrasting regional differences in practice
- Coverage of the 15th International Kidney Cancer Symposium
Generated five 800-word articles on selected talks within 6 hours
- Other **executive summaries** include:
 - CAR-T therapy
 - Secondary immunodeficiency (SID) from immunotherapy
 - Melanoma
 - Y-90 resin microspheres for the treatment of liver metastases

Strategic Meetings

Meetings for several pharmaceutical companies on pipeline development and/or marketing strategy

- Internal strategic meetings concerning pipeline development, publication strategy, marketing, and medical affairs
- Strategic meetings with input from physician advisors
- Disease areas are confidential and thus are not listed

Writing for the General Public

- Summarized 12 primary research articles for the interested general public for use in the **Argonne National Laboratory Advanced Photon Source Annual Report** through:
 - Communication with the primary authors of manuscripts
 - Condensation and organization of complex information on **structural and biophysical research** into clear and understandable synopses
 - Incorporation of author comments into the final article

- Summarized emerging practices in **liver and kidney transplant** for a hospital network outreach plan

EMORY UNIVERSITY

Graduate Research Assistant – 2009 to 2015

- Developed and carried out scientific research protocols for doctoral studies in **virology**, **biochemistry**, **host–pathogen interactions**, **structural biology**, and **genetics**
- Wrote and submitted research grants and authored 4 primary research papers
 - **Vachon VK**, Conn GL. Adenovirus VA RNA: an essential pro-viral non-coding RNA. *Virus Res.* 2016;212:39-52.
 - **Vachon VK**, Calderon BM, Conn GL. A novel RNA molecular signature for activation of 2'-5' oligoadenylate synthetase-1. *Nucleic Acids Res.* 2015;43(1):544-552.
 - Wilson JL, **Vachon VK**, Sunita S, Schwartz SL, Conn GL. Dissection of the adenoviral VA RNAI central domain structure reveals minimum requirements for RNA-mediated inhibition of PKR. *J Biol Chem.* 2014;289(33):23233-23245.
 - **Vachon VK**, Conn GL. Plasmid template design and in vitro transcription of short RNAs within a "structure cassette" for structure probing experiments. *Methods Mol Biol.* 2012;941:157-169.